Quantcast

5 questions about the FDA’s fast-track push for psychedelic treatments

The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions — two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.

Leave a comment

Your email address will not be published. Required fields are marked *

Select the TOP RINO (Republican In Name Only) in Washington.

By completing the poll, you agree to receive emails from BugleCall.org and that you've read and agree to our privacy policy and legal statement.

Bugle Call